Project

Back to overview

JPND - BIOMARKAPD

Applicant Hock Christoph
Number 141625
Funding scheme Joint Programming
Research institution Abteilung für Psychiatrische Forschung Psychiatrische Universitätsklinik Zürich
Institution of higher education University of Zurich - ZH
Main discipline Neurophysiology and Brain Research
Start/End 01.05.2012 - 31.12.2015
Approved amount 497'129.00
Show all

All Disciplines (2)

Discipline
Neurophysiology and Brain Research
Neurology, Psychiatry

Keywords (3)

Alzheimer's Disease; Parkinson; Biomarker

Lay Summary (English)

Lead
Lay summary

This project aims at diagnosing neurodegenerative conditions such as Alzheimer and Parkinson disease prior to clinically overt disease by use of biomarkers. Towards this aim, 48 European and 1 Canadian research center have joined forces to establish criteria and procedures for the use of candidate biomarkers as well as the framework to identify novel and better biomarkers in the future.

Biomarker-absed early diagnosis of neurodegenerative diseases is considered an important condition to initiative preventive therapies in the future. The project includes work on standardizing operating procedures for sample collection, storage, analytical procedures and clinical application of biomarkers, creating assay qualification algorithms, creating networks of harmonized laboratories, as well as defining workflows for the discovery of novel biomarkers
Direct link to Lay Summary Last update: 21.02.2013

Responsible applicant and co-applicants

Employees

Publications

Publication
A practical guide to immunoassay method validation
Andreasson Ulf, Perret-Liaudet Armand, van Doorn Linda J. C. van Waalwijk, Blennow Kaj, Chiasserini Davide, Engelborghs Sebastiaan, Fladby Tormod, Genc Sermin, Kruse Niels, Kuipenj H. Bea, Kulic Luka, Lewczuk Piotr, Mollenhauer Brit, Mroczko Barbara, Pametti Lucille, Vanmechelen Eugeen, Verbeek Marcel M., Winblad Bengt, Zetterberg Henrik, Koel-Simmelink Marleen, Teunissen Charlotte E. (2015), A practical guide to immunoassay method validation, in FRONTIERS IN NEUROLOGY, 6, 216.
The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases
Reijs Babette L. R., Teunissen Charlotte E., Goncharenko Nikolai, Betsou Fay, Blennow Kaj, Baldeiras Ines, Brosseron Frederic, Cavedo Enrica, Fladby Tormod, Froelich Lutz, Gabryelewicz Tomasz, Gurvit Hakan, Kapaki Elisabeth, Koson Peter, Kulic Luka, Lehmann Sylvain, Lewczuk Piotr, Lleo Alberto, Maetzler Walter, de Mendonca Alexandre, Miller Anne-Marie, Molinuevo Jose L., Mollenhauer Brit, Parnetti Lucilla, Rot Uros (2015), The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases, in FRONTIERS IN NEUROLOGY, 6, 216.

Collaboration

Group / person Country
Types of collaboration
JPND Consortium BIOMARKAPD Sweden (Europe)
- in-depth/constructive exchanges on approaches, methods or results
- Publication

Abstract

Scientific abstract of the project (max. 1/2 page) Neurodegenerative disorders, represented mostly by Alzheimer’s disease (AD) and Parkinson’s disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain’s known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to be most effective if the treatment is initiated as early as possible in the disease process. However, clinical manifestations in early disease stages are often difficult to diagnose. This is where biomarkers, specifically reflecting the onset of pathology may have a profound impact on diagnosis and detection of treatment effects in the near future. A triplet of cerebrospinal fluid (CSF) biomarkers for AD, total and hyperphosphorylated tau that reflect AD-type axonal degeneration, and the 42 amino acid isoform of amyloid that reflects senile plaque pathology, has already been established for early detection of AD before the onset of dementia. With regards to PD, the most promising biomarker is CSF -synuclein. However, large variations in all biomarker measurements have been reported between studies, both between and within centres and laboratories. Such variations may be caused by pre-analytical, analytical, or assay-related factors and seriously jeopardize the introduction of biomarkers in clinical routine and trials around the world. The aim of BIOMARKAPD is to standardise the assessment of established and new fluid biomarkers for AD and PD. To this end we will: - Create and validate detailed standardised operating procedures for sample collection, storage, analytical procedures and clinical use of biomarkers for AD and PD. - Create an assay qualification algorithm specifying technical characteristics that must be fulfilled to employ the assay in AD and PD biomarker studies and in clinical routine and trials. - Create a network of harmonised laboratories around Europe and also implement a certification system for laboratories and technicians with yearly hands-on training events and external quality control surveys four times per year. - Define a workflow for how new biomarkers can be developed from proof of concept studies to established biomarkers with reference limits, cut-offs and controlled confounders. - Build a biobank for validating new biomarker candidates. - Establish certified reference materials for biomarker measurements. This is by far the most ambitious AD and PD biomarker standardisation programme to date, covering the whole of Europe, as well as one Canadian site. The harmonisation of biomarker-related procedures across Europe will facilitate clinical trials and allow for general implementation of the newly proposed diagnostic guidelines for AD and new diagnostic approaches for PD in clinical routine.
-